Zacks
EHC Expands in Tennessee Via New JV Facility With Vanderbilt Health
📈
AI Sentiment
Highly Positive
8/10
- Home
- BSX
as of 11-28-2025 12:36pm EST
$101.50
+$0.54
+0.53%
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
Chart Type:
Time Range:
| Founded: | 1979 | Country: | United States |
| Employees: | N/A | City: | MARLBOROUGH |
| Market Cap: | 149.7B | IPO Year: | 1992 |
| Target Price: | $124.53 | AVG Volume (30 days): | 8.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 19 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.87 | EPS Growth: | 54.68 |
| 52 Week Low/High: | $85.98 - $109.50 | Next Earning Date: | 10-22-2025 |
| Revenue: | $19,349,000,000 | Revenue Growth: | 21.61% |
| Revenue Growth (this year): | 21.04% | Revenue Growth (next year): | 11.45% |
AI-Powered BSX Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 69.08%
69.08%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Boston Scientific Corporation (BSX)
Zane Ellen M
Sell
Director
BSX Nov 6, 2025
Avg Cost/Share
$98.28
Shares
12,891
Total Value
$1,266,977.75
Owned After
24,134
SEC Form 4
Fitzgerald Joseph Michael
Sell
EVP & Group Pres, Cardiology
BSX Nov 3, 2025
Avg Cost/Share
$99.88
Shares
50,000
Total Value
$4,973,337.63
Owned After
207,814
Zane Ellen M
Sell
Director
BSX Oct 28, 2025
Avg Cost/Share
$102.24
Shares
2,901
Total Value
$296,598.82
Owned After
24,134
SEC Form 4
Zane Ellen M
Sell
Director
BSX Oct 27, 2025
Avg Cost/Share
$101.13
Shares
9,990
Total Value
$1,010,300.69
Owned After
24,134
SEC Form 4
Fitzgerald Joseph Michael
Sell
EVP & Group Pres, Cardiology
BSX Oct 1, 2025
Avg Cost/Share
$98.64
Shares
50,000
Total Value
$4,923,326.82
Owned After
207,814
Fitzgerald Joseph Michael
Sell
EVP & Group Pres, Cardiology
BSX Sep 2, 2025
Avg Cost/Share
$105.37
Shares
50,000
Total Value
$5,271,416.44
Owned After
207,814
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Zane Ellen M | BSX | Director | Nov 6, 2025 | Sell | $98.28 | 12,891 | $1,266,977.75 | 24,134 | |
| Fitzgerald Joseph Michael | BSX | EVP & Group Pres, Cardiology | Nov 3, 2025 | Sell | $99.88 | 50,000 | $4,973,337.63 | 207,814 | |
| Zane Ellen M | BSX | Director | Oct 28, 2025 | Sell | $102.24 | 2,901 | $296,598.82 | 24,134 | |
| Zane Ellen M | BSX | Director | Oct 27, 2025 | Sell | $101.13 | 9,990 | $1,010,300.69 | 24,134 | |
| Fitzgerald Joseph Michael | BSX | EVP & Group Pres, Cardiology | Oct 1, 2025 | Sell | $98.64 | 50,000 | $4,923,326.82 | 207,814 | |
| Fitzgerald Joseph Michael | BSX | EVP & Group Pres, Cardiology | Sep 2, 2025 | Sell | $105.37 | 50,000 | $5,271,416.44 | 207,814 |
Latest Boston Scientific Corporation News
BSX Breaking Stock News: Dive into BSX Ticker-Specific Updates for Smart Investing
Zacks
GEHC Stock Gains Post Latest Launch to Optimize Radiology Workflows
📈
AI Sentiment
Highly Positive
8/10
Simply Wall St.
Is Boston Scientific (NYSE:BSX) A Risky Investment?
📈
AI Sentiment
Highly Positive
8/10
GlobeNewswire
Pediatric Interventional Cardiology Market Competitive Landscape Report 2025: Recent Developments, Strategies, Sustainability Benchmarking, Product Analysis, Key Persons and Revenue
📈
AI Sentiment
Highly Positive
8/10
MedTech Dive
CMS covers cardiac ablation in ambulatory surgery centers
📈
AI Sentiment
Highly Positive
8/10
Zacks
Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term
📊
AI Sentiment
Positive
7/10
Zacks
Boston Scientific's Margins Strengthen in Q3: What's Driving It?
📈
AI Sentiment
Highly Positive
8/10
StockStory
Q3 Earnings Roundup: Boston Scientific (NYSE:BSX) And The Rest Of The Medical Devices & Supplies - Diversified Segment
📊
AI Sentiment
Positive
7/10
Compare BSX vs Leading Stocks
See how BSX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "BSX Boston Scientific Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.